PETALING JAYA: Good news for patients who could not afford an exorbitant medicine for an aggressive type of breast cancer.
The Health Ministry has approved the biosimilar version of trastuzumab (a monoclonal antibody), a targeted therapy, for women with HER2-positive breast cancer patients, said Dr Dzulkefly Ahmad.
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
